Estramustine phosphate versus stilbestrol as primary treatment for metastatic cancer of the prostate.
A controlled, randomized trial of estramustine phosphate versus stilbestrol has been conducted in patients with previously untreated adenocarcinoma of the prostate. Both drugs were equally effective in decreasing serum testosterone and acid phosphatase levels. No therapeutic advantage of estramustine over stilbestrol was noted. At 3 months, 50% of tumours treated with stilbestrol had regressed compared with 36% treated with estramustine, at 1 year the rates were 50% and 21% respectively and at 2 years 50% and 9%. However, there was no difference in objective stabilization and regression rates between the two groups or in therapeutic failure rates.
D000135:Acid Phosphatase / Q000097:blood; D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D002986:Clinical Trials as Topic; D004054:Diethylstilbestrol / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004961:Estramustine / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D011388:Prolactin / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011897:Random Allocation; D013739:Testosterone / Q000097:blood
D009588:Nitrogen Mustard Compounds; D004961:Estramustine; D013739:Testosterone; D004054:Diethylstilbestrol; D011388:Prolactin; D000135:Acid Phosphatase